ClinicalTrials.gg
RecruitingNCT07610967LIGHTUpdated Oct 26, 2026

Light-based Immunomodulation for Guarding Against Human Respiratory Tract Infections

An interventional study of RD-X19 and RD-X19 Sham in COVID-19 Respiratory Infection and Influenza, sponsored by David Moss. Recruiting at 1 site in United States. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-10-26.

Sponsored by David Moss · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Oct 2026; still recruiting 1 month later.
Updated Oct 8, 2026Now RecruitingFirst site in United States+1 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
130
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 966 studies in Influenza, Human with a site in United States — 60 open to participants now, 85 under way, 7 of them phase 3. Influenza, Human · United States.

Planned enrollment
527th of 843
130 · median 270
Started
2026
with 26 others
No phase
160 of 966
13 open now
Primary completion
2028-06
later than 68 of 83 live
Registered
951st of 966
by date

Among the 966 studies in Influenza, Human with a site in United States, this one is the 527th largest by planned enrollment of the 843 interventional ones that give a count, is one of 27 that started in 2026, is one of 160 with no phase, reaches primary completion later than 68 of the 83 other live ones, and was the 951st registered.

Influenza, Human

2,361 studies on the registry are indexed under Influenza, Human; 186 are open to participants now.

Browse Influenza, Human studies →

Open to participants now

60 of the 966 studies in Influenza, Human with a site in United States are open now. Recruiting first, the newest first:

54 more — sign in →

All 60 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 124 Influenza, Human studies recruiting now, 67 (54%) set no upper age limit and 47 (38%) stop at 75 or younger; 34 take children under 18; 69 take healthy volunteers.

This study: 18 Years and older · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 966 studies in Influenza, Human with a site in United States, or all of them as a file.
02

Study summary

The purpose of trial is to determine if daily usage of a photobiomodulation device will decrease the incidence of upper respiratory tract infections (URI) due to COVID, influenza or other viruses.The RD-X10 device is handheld, can be self-administered, and has been shown to be safe in invivo studies.

Read the detailed description

Methods: Subjects 18 years and older working at a DoD medical facility and VA medical facility will be randomized into Active Treatment (Emit Bio ) and sham (inactive device). Basic demographic information will be obtained. Subjects will use the device at home every other day for 5 minutes. Baseline viral upper respiratory PCR panel will be obtained to ensure pre-existing infections are not counted. At first sign of upper respiratory infection symptoms, subjects will contact research personnel and have viral respiratory PCR panel obtained. Research coordinators will also contact subjects every two weeks to ask if they are experiencing or have experienced any upper respiratory symptoms or if they have experienced any side effects of treatment. Subjects reporting any current symptoms or symptoms in the prior 2 weeks will have upper respiratory PCR panel obtained. Any subjects with confirmed or unconfirmed PCR URI will be contacted daily until symptoms subside to assess secondary outcomes including duration of symptoms, missed days of work, outpatient medical visits, ED visits, hospitalizations, medication prescriptions for respiratory illness and over the counter treatments.

Screening visit (Approx 30 min):

  • Obtain and document signed Informed Consent document and HIPAA Authorization
  • Verify subject eligibility based on inclusion/exclusion criteria (research coordinators may use the electronic medical record to verify inclusion/exclusion)
  • Record all medications the subject is taking
  • Collect demographic information to include phone number, email address, DoD ID, age, race, ethnicity, sex, whether they directly care for patients, what department they work in, any therapies regularly used to prevent URI (ie zinc, mouth washes, supplements), and immunocompromised state or medications that may suppress the immune system, weight (pounds), height (inches), and BMI

Randomization:

Subjects will be randomized using block randomization (blocks of 6) into one of two research treatment groups, with approximately 50 subjects in each arm for a total of 100 subjects. The study staff assigning subjects to their group will be unblinded to the groups, but patients, investigators, and study staff conducting screening and gathering data will be blinded. The unique study code will be assigned in sequential order beginning with 001.

Group 1: Active RD-X19 every other day for 3 months Group 2: Sham RD-X19 every other day for 3 months

Visit 1 (week 0) (may be same day as screening visit) (approx. 30 minutes):

  • Subject will be given the RD-X19 device and shown how to use the device
  • Subjects will be instructed to use the device for 5 minutes every other day
  • Subject will be given "Instructions for Treatment" handout
  • Obtain a baseline PCR panel using a nasal swab

Visits 2-7 (weeks 2-12) (approx. 30 min) can be performed virtually or in person

  • Subjects will be asked if they have experienced any upper respiratory symptoms in the last 2 weeks, this may include cough, congestion, sore throat, fatigue, runny nose, sinus pain or pressure, fever (subjective or Temp >100 F), sneezing.
  • Subjects experiencing any of the above symptoms will be tested for URI causing viruses using PCR based testing.
  • Any subjects with confirmed or unconfirmed PCR URI will be contacted daily until symptoms subside to assess secondary outcomes including duration of symptoms, missed days of work, outpatient medical visits, ED visits, hospitalizations, medication prescriptions for respiratory illness and over the counter treatments. They will also be assessed daily using the WURSS 24 (Wisconsin Upper Respiratory Symptom Survey) daily symptom report until they report a score of 0 for question 1 (How sick do you feel today?)
  • Subjects who have not experienced any URI symptoms will be assessed for adherence to RDX19 over the previous 2 weeks and encouraged to continue using the device. They will also be asked if they are experiencing any side effects of the treatment such as throat or mouth irritation, sores in the mouth or on the lips or any other perceived side effects.
  • At the end of each study visit, subjects will be asked if the device was used as directed.

Visit 7

-During the subjects final visit, they will be given a questionnaire regarding usage of the device

Device will only be used for a single patient and should be returned to research staff at the end of the study for disposal.

03

Conditions studied

  • COVID-19 Respiratory Infection
  • Influenza

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Active Duty and DoD Beneficiaries (i.e. former military, spouse, dependent child) aged 18 years and older who work in the Mike O'Callaghan Military Medical Center at Nellis Air Force Base.

Exclusion criteria

Exclusion Criteria:

  • Unable to comfortably insert RD-X19 into the mouth and keep in place for 5 minutes
  • Plans for head, neck or mouth surgery during the study period
  • Plans for major dental procedures (ie implants, wisdom teeth extraction etc) during the study
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
130 participants (estimated)

Study arms

  • Experimental
    Group 1: Active RD-X19 every other day for 3 months

    Device: RD-X19

  • Sham comparator
    Group 2: Sham RD-X19 every other day for 3 months

    Device: RD-X19 Sham

Interventions

  • DeviceRD-X19

    * Subject will be given the RD-X19 device and shown how to use the device * Subjects will be instructed to use the device for 5 minutes every other day * Subject will be given "Instructions for Treatment" handout

  • DeviceRD-X19 Sham

    * Subject will be given the sham RD-X19 device and shown how to use the device * Subjects will be instructed to use the sham device for 5 minutes every other day * Subject will be given "Instructions for Treatment" handout

06

What researchers measure

Primary outcomes

  1. difference in PCR confirmed URI (any virus)

    difference in PCR confirmed URI (any virus) between active and sham groups between treatment period

    Time frame: visit 2 (week 2), visit 3 (week 4), visit 4 (week 6), visit 5 (week 8), visit 6 (week 10), visit 7 (week 12)

Secondary outcomes

  1. duration of symptoms

    Any subjects with confirmed or unconfirmed PCR URI will be contacted daily until symptoms subside to assess duration of symptoms (days)

    Time frame: upper respiratory infection duration, an average of 2 weeks

  2. missed days of work

    Any subjects with confirmed or unconfirmed PCR URI will be contacted daily until symptoms subside to assess missed days of work

    Time frame: upper respiratory infection duration, an average of 2 weeks

  3. outpatient visits

    Any subjects with confirmed or unconfirmed PCR URI will be contacted daily until symptoms subside to assess number of outpatient visits

    Time frame: upper respiratory infection duration, an average of 2 weeks

  4. emergency department visits

    Any subjects with confirmed or unconfirmed PCR URI will be contacted daily until symptoms subside to assess number of emergency department visits

    Time frame: upper respiratory infection duration, an average of 2 weeks

  5. hospitalizations

    Any subjects with confirmed or unconfirmed PCR URI will be contacted daily until symptoms subside to assess number of hospitalizations

    Time frame: upper respiratory infection duration, an average of 2 weeks

  6. Wisconsin Upper Respiratory Symptom Survey (WURSS 24)

    Any subjects with confirmed or unconfirmed PCR URI will be contacted daily until symptoms subside to assess daily symptom severity score using WURSS 24. The WURSS 24 is an illness-specific quality of life instrument, designed to assess the negative impact of acute upper respiratory infections. Subjects rate their symptoms and daily impairments using 0-7-point Likert scales. Minimum value is 0, maximum value is 154. Higher score means worse outcome.

    Time frame: upper respiratory infection duration, an average of 2 weeks

  7. number and type of medication prescriptions for respiratory illness

    Any subjects with confirmed or unconfirmed PCR URI will be contacted daily until symptoms subside to assess number and type medication prescriptions for respiratory illness. Example: 1 medication prescription, medication prescription=Tamiflu.

    Time frame: upper respiratory infection duration, an average of 2 weeks

  8. number and type of over the counter treatments used

    Any subjects with confirmed or unconfirmed PCR URI will be contacted daily until symptoms subside to assess number an d type of over the counter treatments used. Example: 1 OTC treatment used, OTC treatment=ibuprofen.

    Time frame: upper respiratory infection duration, an average of 2 weeks

  9. differences in incidence of URI amongst different viruses from PCR panels

    differences in incidence of URI amongst different viruses from PCR panels

    Time frame: through study duration, an average of 12 weeks

  10. treatment side effects

    treatment side effects

    Time frame: through study duration, an average of 12 weeks

  11. adherence to daily use of RD-X19 device throughout study

    adherence to daily use of RD-X19 device as reported to study staff at all visits (1-7)

    Time frame: through study duration, an average of 12 weeks

07

Study locations

1 of 1 sites recruiting
08

References and documents

Publications

  • Stasko N, Arwood L, Jandick N, Spragion D, Roberts RC, Setien M, Henson I, Annas A, Fulcher ML, Brotton M, Kummer L, Szaba F, Reagan M, Lanzer K, Cookenham T, Casey S, Kothapalli N, Hart T, Bradrick SS, Emerson D, Cockrell AS, Randell SH, Kocher JF. The pan-variant potential of light: 425 nm light inactivates SARS-CoV-2 variants of concern and non-cytotoxic doses reduce viral titers in human airway epithelial cells. mSphere. 2025 Jun 25;10(6):e0023025. doi: 10.1128/msphere.00230-25. Epub 2025 May 28. PubMed 40434113 ↗
  • Gibson S, Saunders R, Stasko N, Bickerstaff CB, Oakley J, Osterman M, Torres RT, Kish JK, Feinberg BA, Emerson D. Economic and clinical impact of a novel, light-based, at-home antiviral treatment on mild-to-moderate COVID-19. J Med Econ. 2022 Jan-Dec;25(1):503-514. doi: 10.1080/13696998.2022.2055370. PubMed 35387539 ↗
  • Stasko N, Cockrell AS, Kocher JF, Henson I, Emerson D, Wang Y, Smith JR, Henderson NH, Wood H, Bradrick SS, Jones T, Santander J, McNeil JG. A randomized, controlled, feasibility study of RD-X19 in subjects with mild-to-moderate COVID-19 in the outpatient setting. Clin Transl Sci. 2022 May;15(5):1291-1303. doi: 10.1111/cts.13249. Epub 2022 Feb 27. PubMed 35137532 ↗
  • Zupin L, Gratton R, Fontana F, Clemente L, Pascolo L, Ruscio M, Crovella S. Blue photobiomodulation LED therapy impacts SARS-CoV-2 by limiting its replication in Vero cells. J Biophotonics. 2021 Apr;14(4):e202000496. doi: 10.1002/jbio.202000496. Epub 2021 Mar 1. PubMed 33619888 ↗
  • Stasko N, Kocher JF, Annas A, Henson I, Seitz TS, Miller JM, Arwood L, Roberts RC, Womble TM, Keller EG, Emerson S, Bergmann M, Sheesley ANY, Strong RJ, Hurst BL, Emerson D, Tarbet EB, Bradrick SS, Cockrell AS. Visible blue light inhibits infection and replication of SARS-CoV-2 at doses that are well-tolerated by human respiratory tissue. Sci Rep. 2021 Oct 18;11(1):20595. doi: 10.1038/s41598-021-99917-2. PubMed 34663881 ↗
  • Stockslager MA, Kocher JF, Arwood L, Stasko N, McDonald RA, Tapsak MA, Emerson D. Efficacy and hazards of 425 nm oral cavity light dosing to inactivate SARS-CoV-2. J Dent. 2022 Aug;123:104203. doi: 10.1016/j.jdent.2022.104203. Epub 2022 Jun 17. PubMed 35724941 ↗
  • Kuster SP, Shah PS, Coleman BL, Lam PP, Tong A, Wormsbecker A, McGeer A. Incidence of influenza in healthy adults and healthcare workers: a systematic review and meta-analysis. PLoS One. 2011;6(10):e26239. doi: 10.1371/journal.pone.0026239. Epub 2011 Oct 18. PubMed 22028840 ↗
  • Demmler-Harrison GJ. Healthcare-Associated Viral Infections: Considerations for Nosocomial Transmission and Infection Control. Healthcare-Associated Infections in Children. 2018;229-257. Published 2018 Jul 16. doi:10.1007/978-3-319-98122-2_14

Individual participant data

Plan to share: Yes — Demographic and clinical data will be acquired from participants. All data will be de-identified prior to receipt by the repository, but the information needed to generate a global unique identifier for the NLM Data Archive (NDA) (clinicaltrials.gov) will be collected for each subject. Sufficient data from this project will be preserved to enable sharing via NDA data of sufficient quality to validate and replicate research findings described in the Aims. NLM requires data measured from human subjects to be shared using the NDA. Demographic data, clinical data, data collection tools and study protocols will be made available in the NDA.

Supporting information: Study protocol, Statistical analysis plan, Informed consent form

Time frame: All data will be deposited to clinicaltrials following the usual NDA data submission dates.

Access criteria: Data will be findable for the research community through the NDA Collection that will be established when this application is funded. For all publications, an NDA study will be created. Each of those studies is assigned a digital object identifier (DOI). This data DOI will be referenced in the publication to allow the research community easy access to the exact data used in the publication. The research community will have access to data when the study ends. As required by NDA, studies will also be created that contain the data used for every publication. Those studies will be shared when the pre-print is available. NDA studies have digital object identifiers (DOI) to aid in findability. We will include that DOI in relevant publications. NDA will make decisions about how long to preserve the data, but that data archive has not deleted any deposited data up to now.

09

Timeline

2 registry updates since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Oct 2026 (actual). Primary completion is estimated for Jun 2028, 20 months after the start.

Of 147 non-industry interventional studies with no phase under Influenza, Human, half reached primary completion within 7 months of starting (the median), counting those still running; a quarter within 3 and three quarters within 18. This study's planned 20 months is above that.

Counting every sponsor, half of 167 studies reached it within 6 months; a quarter within 3 and three quarters within 16.

How these figures are worked out, and which studies are left out of them.

Registered
May 14, 2026
First posted
May 28, 2026
StartActual
Oct 1, 2026
Primary completionEst.
Jun 2028
CompletionEst.
Jun 2028
Last update
Oct 26, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Not yet recruiting→Recruiting
changed Oct 8, 2026
Sites
1 site added — first site in United States
Show site
  • Mike O'Callaghan Military Medical Center · Nellis Air Force Base, United States
Oct 8, 2026
Show all 2 updates
  1. Oct 26, 2026
    Minor edits only
    + 1 other change: description
  2. Oct 8, 2026
    Not yet recruiting→Recruiting
    1 site added — first site in United States
    Show site
    • Mike O'Callaghan Military Medical Center · Nellis Air Force Base, United States
    + 2 other changes: verification date and date precision

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07610967
Lead sponsor
David Moss
Responsible party
David Moss (Principal Investigator/ Doctor, Mike O'Callaghan Military Hospital) — Sponsor-investigator
First posted
May 28, 2026
Start date
Oct 1, 2026
Primary completion
Jun 2028 (estimated)
Completion
Jun 2028 (estimated)
Last update
Oct 26, 2026

Study contacts

Sandra Huffman
Contact
Sandra.g.huffman.ctr@health.mil
7026533583

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion